Ozepic says he reduces his desire to consume alcoholic beverages, he says

Semaglutado, one of the best -selling drugs marketed by the new Danish Nordisk company, added a potential indicator to the benefit list for diabetes such as Semaglutado, Özempic, Wegovy for obesity: a 30% decrease in daily alcohol consumption for people receiving medication.

According to an article recently published in Psychiatry, “In the randomized clinical research on placebo, low dose Semagluttado reduced the amount of alcohol consumed during a post -treatment laboratory application procedure”.

For the first author of the study, Christian Hendershot, a psychiatrist at the University of North Carolina, USA, not only reduced consumption in people with symptoms of alcohol use compared to a placebo fields. It also reduced the patient’s desire for matter.

Test alcohol consumption in the laboratory

For the test, the authors chose 34 women and 34 women who were diagnosed with alcohol use disorder that was not actively treated for this situation. Popularly known as alcoholism, chronic disease is characterized by their main symptoms. Inability to interrupt or control alcohol consumptionEven if this causes personal problems.

Before the first injection, participants drank their favorite alcohol for two hours in the laboratory and may postpone consumption if they wish. When they register the delays and drinks consumed, they are randomly divided by continuous monitoring of alcohol consumption for nine -week weekly. Then they returned to the laboratory to repeat the first experiment.

The results showed that the participants receiving Semagluter injections consumed less alcohol in the laboratory and that they were measured by concentration of gram and breath consumed. Clinical assessments revealed that a decrease in weekly alcohol desire, lower drinking days and heavy consumer parts compared to placebo, which is potentially more effective than existing drugs for you.

Semaglutado’s importance in reducing the desire for alcohol

A secondary but less important result observed in the study was that there was a significant decrease in average cigarettes per day compared to that of the placebo group of those treated with Semagtutado at the beginning of the study between a small subgroup who smokes while drinking.

Currently, alcohol and cigarette consumption are the main causes that can be prevented with obesity, mortality and cancer deaths. Therefore, although this decrease is observed in the placebo group only seven people and in the treatment group, the discovery is very important because it is very important because So far, there is no approved medication to reduce alcohol and stop smoking.

Although the authors are encouraging, they warn that these data are still preliminary and demanding a higher cohort of reducing the number of participants. With the increase in clinical use of the drug, more studies will be needed to evaluate long -term effects on alcohol consumption and the ideal doses and treatment periods that should be different from those shown for diabetes and obesity.

Possible Semaglutado applications in treatments

Klara Klein, a professor at the University of North Carolina in the United States, the senior writer of the study, should focus on future research on the focus of GLP-1 receptor agonists who help control the appetite on reducing the cause of alcohol. In a statement, the doctor stated that these effects are probably mediating in the brain and that this organ has evaluated and responded to the stimuli that creates pleasure or satisfaction.

It is important to emphasize that Semaglutado, an original drug developed for Type 2 diabetes treatment, is useful in the treatment of obesity and in a series of unexpected situations. such as osteoarthritis, liver steatosis, dementia and kidney diseases.

However, as in any drug, Semaglutado may have more common and temporary side effects such as nausea; And others are more serious and rare like shrinkage of heart muscles. The reason for this is that the drug changes body biochemistry with positive and negative results that continue to be discovered and evaluated over time.

Would you like to learn more about the unexpected effects of drugs? Learn the uncertain and deadly side of the obsession of society by Özempik and interpret your interpretation of our social networks and possible experiences about the resulting treatments. Next time.